跳至主要内容
临床试验/NCT02000388
NCT02000388Unknown4 期

Efficacy and Safety of Intranasal Ketorolac Tromethamine (SPRIX) as a Short Term Pain Management Tool for Adult Male Patients With Post-Vasectomy Pain

Citrus Valley Medical Research, Inc.0 个研究点目标入组 15 人开始时间: 2012年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
发起方
入组人数
15
主要终点
Pain Scores on the Visual Analog Scale

研究概览

简要总结

To evaluate the efficacy, tolerability and safety of intranasal ketorolac tromethamine (SPRIX) as an option for pain management in post vasectomy patients.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
25 Years 至 64 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Ketorolac tromethamine (SPRIX)

Other

A SPRIX dose will be one 15.75 mg spray in each nostril for a total dose of 31.5 mg which can be repeated every 6-8 hrs as needed for post vasectomy pain with a maximum daily dose of 126 mg to be continued for up to 5 days.

干预措施: Ketorolac Tromethamine (Drug)

Standard of care

Other

The intervention used will be standard of care

干预措施: Standard of Care (Other)

结局指标

主要结局

Pain Scores on the Visual Analog Scale

时间窗: 5 days

次要结局

  • To determine Number of Participants with Adverse Events as a Measure of Safety and Tolerability(5 Days)

研究者

发起方
Citrus Valley Medical Research, Inc.
申办方类型
Other
责任方
Sponsor

相似试验